key: cord-0314857-tpkb4928 authors: Tenbusch, M.; Schumacher, S.; Vogel, E.; Priller, A.; Held, J.; Steininger, P.; Beileke, S.; Irrgang, P.; Brockhoff, R.; Salmanton-Garcia, J.; Tinnefeld, K.; Mijocevic, H.; Schober, K.; Bogdan, C.; Yazici, S.; Knolle, P.; Cornely, O. A.; Ueberla, K.; Protzer, U. title: Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA date: 2021-07-06 journal: nan DOI: 10.1101/2021.07.03.21258887 sha: f7b226f83d3e35396ad16c5ea72605ac28c8251e doc_id: 314857 cord_uid: tpkb4928 Administration of a first dose of the COVID-19 vaccine ChAdOx1 nCoV-19 (Vaxzevria(R), AstraZeneca) is associated with a certain risk for vaccine-induced immune thrombotic thrombocytopenia. Therefore, several countries have recommended replacing the second dose of ChAdOx1 nCoV-19 with an mRNA-based vaccine as a precautionary measure, although data on safety and efficacy of such heterologous prime-boost regimen are sparse. Therefore, vaccinees, who had received a heterologous vaccination using ChAdOx1 nCoV-19 as prime and BNT162b2 (Comirnaty(R), BioNTech-Pfizer) mRNA as boost vaccination were offered SARS-CoV-2 antibody testing to quantify their vaccine-induced neutralizing antibody response. The results were compared to cohorts of healthcare workers or volunteers, who received homologous BNT162b2 or homologous ChAdOx1 nCoV-19 vaccination regimens, respectively. A striking increase of vaccine-induced SARS-CoV-2 neutralizing antibody activity was observed in 229 vaccinees that received a BNT162b2 boost 9 to 12 weeks after ChAdOx1 nCoV-19 prime. In our cohort comprising over 480 individuals, the heterologous vaccination scheme induced significantly higher neutralizing antibody titers than homologous ChAdOx1 nCoV-19 and even than homologous BNT162b2 vaccination. This proves that a single dose of a COVID-19 mRNA vaccine after ChAdOx1 nCoV-19 prime vaccination is sufficient to achieve high neutralizing antibody levels predicting immune protection from SARS-CoV-2 infection, and may even increase vaccine efficacy offering an alternative in a setting of vaccine shortage. Outside of the study, UP received grants from ALIOS and VirBio and personal fees from Abbvie, Arbutus, Gilead, GSK, J&J, Roche, Sobi, and Vaccitech. UP is co-founder and share-holder of SCG Cell Therapy. OAC received grants from Janssen, grants and personal fees from Merck/MSD, grants and personal fees from Pfizer, outside the submitted work. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi. org/10.1101 org/10. /2021 Abstract: Administration of a first dose of the COVID-19 vaccine ChAdOx1 nCoV-19 (Vaxzevria ® , AstraZeneca) is associated with a certain risk for vaccine-induced immune thrombotic thrombocytopenia. Therefore, several countries have recommended replacing the second dose of ChAdOx1 nCoV-19 with an mRNA-based vaccine as a precautionary measure, although data on safety and efficacy of such heterologous prime-boost regimen are sparse. Therefore, vaccinees, who had received a heterologous vaccination using ChAdOx1 nCoV-19 as prime and BNT162b2 (Comirnaty ® , BioNTech-Pfizer) mRNA as boost vaccination were offered SARS-CoV-2 antibody testing to quantify their vaccine-induced neutralizing antibody response. The results were compared to cohorts of healthcare workers or volunteers, who received homologous BNT162b2 or homologous ChAdOx1 nCoV-19 vaccination regimens, respectively. A striking increase of vaccine-induced SARS-CoV-2 neutralizing antibody activity was observed in 229 vaccinees that received a BNT162b2 boost 9 to 12 weeks after ChAdOx1 nCoV-19 prime. In our cohort comprising over 480 individuals, the heterologous vaccination scheme induced significantly higher neutralizing antibody titers than homologous ChAdOx1 nCoV-19 and even than homologous BNT162b2 vaccination. This proves that a single dose of a COVID-19 mRNA vaccine after ChAdOx1 nCoV-19 prime vaccination is sufficient to achieve high neutralizing antibody levels predicting immune protection from SARS-CoV-2 infection, and may even increase vaccine efficacy offering an alternative in a setting of vaccine shortage. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.03.21258887 doi: medRxiv preprint Administration of a first dose of the COVID-19 vaccine ChAdOx1 nCoV-19 (Vaxzevria ® , AstraZeneca) is associated with a risk for vaccine-induced immune thrombotic thrombocytopenia (VITT; also termed thrombosis thrombocytopenia syndrome, TTS) in the range of one to two cases per 100,000 vaccinations, with younger women showing the highest risk 1,2 . Fewer cases have been reported for the Ad26.COV2.S COVID-19 vaccine Janssen (Johnson & Johnson), another adenoviral-vector based COVID-19 vaccine 3 . As vaccine-induced antibodies against platelet factor 4 (PF4) have been implicated in the pathogenesis of VITT 1, 2 , an amplifying effect of a second vaccine dose cannot be excluded. Therefore, several countries have recommended replacing the second dose of ChAdOx1 nCoV-19 with an mRNA-based vaccine as a precautionary measure, although data on safety and efficacy of such heterologous prime-boost regimen are sparse or even absent 4 . Considering these uncertainties, vaccinees, who had received a heterologous vaccination using ChAdOx1 nCoV-19 as prime and BNT162b2 (Comirnaty ® , BioNTech-Pfizer) mRNA as boost vaccination were offered SARS-CoV-2 antibody testing to quantify their vaccineinduced neutralizing antibody response 5 . The results were compared to cohorts of healthcare workers or volunteers, who received homologous BNT162b2 or homologous ChAdOx1 nCoV-19 vaccination regimens, respectively. Demographic data of the cohorts analyzed are presented in the Supplementary Appendix (Table S1 and S2). To assess protective antibody responses, a surrogate neutralization assay (NAb assay, Yhlo, Shenzen, China) based on the competition of serum antibodies with recombinant angiotensin-converting-enzyme 2 for binding to the SARS-CoV-2 spike protein receptorbinding domain was performed in two certified, university virology diagnostic laboratories in Munich and Erlangen. Importantly, the surrogate neutralization assay correlated closely with a cell-culture based SARS-CoV-2 neutralization assay (Supplementary Appendix, Figure S1 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.03.21258887 doi: medRxiv preprint A striking increase of vaccine-induced SARS-CoV-2 neutralizing antibody activity was observed in 229 vaccinees that received a BNT162b2 boost 9 to 12 weeks after ChAdOx1 nCoV-19 prime. Sera were analyzed at the day of BNT162b2 boost vaccination and two weeks thereafter ( Figure 1A ). The single non-responder reported chronic lymphatic leukemia. High antibody levels already after ChAdOx1 nCoV-19 prime vaccination in two individuals most likely reflected prior, undetected SARS-CoV-2 infection. Figures 1B and 1C show comparisons of the antibody levels observed two weeks after two doses of BNT162b2, two doses of ChAdOx1 nCoV-19 or one dose of ChAdOx1 nCoV-19 followed by one dose of BNT162b2. The heterologous vaccination induced significantly higher neutralizing antibody titers than homologous ChAdOx1 nCoV-19 and even than homologous BNT162b2 vaccination. Thus, a single dose of a COVID-19 mRNA vaccine after ChAdOx1 nCoV-19 prime vaccination is sufficient to achieve high neutralizing antibody levels predicting immune protection from SARS-CoV-2 infection 5 . These results obtained in over 480 individuals, who received a prime with an adenoviral vector and a boost with an mRNA vaccine, indicate that a heterologous prime-boost with different COVID-19 vaccines may increase vaccine efficacy, and offers an alternative in a setting of vaccine shortage. Further studies, however, need to address the safety and clinical efficacy of heterologous vaccination regimens. (479 words) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 cut-off of the surrogate neutralization assay. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.03.21258887 doi: medRxiv preprint Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients -United States Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted